AUTHORS
Mousa Thalji, MD, Rima M. Saliba, PhD2, Khalid Alharbi, MD3, Celina Ledesma4, Gheath Alatrash, PhD5, Amin Alousi, MD6, Chitra Hosing, MD7, Issa F. Khouri, MD8, Warren Fingrut, MD, MPH9, Qaiser Bashir, MD10, David Marin11, Rohtesh Mehta, MD, MPH12, Muzaffar Qazilbash, MD13, Samer A Srour, MB ChB, MS14, Uday Popat, MD, MBA15, Nitin Jain, MD16, Elias Jabbour, MD17, Nicholas Short, MD18, Farhad Ravandi, MD19, Richard Champlin20, Elizabeth Shpall, MD21, Partow Kebriaei, MD22
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
Relapse of acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic cell transplantation (alloHCT) is associated with poor outcomes and limited curative options. A second alloHCT may provide durable disease control in selected patients; however, available evidence is largely derived from small historical cohorts. We evaluated long-term outcomes and prognostic factors among adults undergoing a second alloHCT for ALL relapse following a first alloHCT.
Methods
We retrospectively analysed consecutive patients aged ≥18 years at second alloHCT who underwent transplantation between January 1, 2000 and December 31, 2025 at our institution for relapsed ALL following a first alloHCT. OS and PFS were estimated using the Kaplan-Meier method and risk factors for these outcomes were evaluated using Cox proportional hazards regression. Non-relapse mortality (NRM) and relapse incidence were estimated accounting for competing risks.using competing-risk methods.
Results
Seventy-seven patients were included. Median age: 31 years (range, 18–69), and median HCT-Comorbidity Index was 2 (range, 0–7). Before second alloHCT, 29 patients (38%) were in second complete remission (CR2), 20 (26%) were in CR3 or later, and 28 (36%) were not in CR. Reduced-intensity and myeloablative conditioning were used in 60 (78%) and 17 (22%) patients, respectively; 32 (42%) received post-transplant cyclophosphamide-based GVHD prophylaxis. Graft sources were peripheral blood in 58 patients (75%), bone marrow in 11 (14%), and cord blood in 8 (10%). Median intervals from first alloHCT to relapse, first to second alloHCT, and relapse to second alloHCT were 14.6, 22.0, and 6.1 months, respectively. Thirty-nine patients (51%) underwent second alloHCT in 2016 or later. Median follow-up among survivors was 45.9 months (range, 2.7–143.6) overall, 69 months (range, 2.7–143.6) in 2001–2015, and 46 months (range, 6–83) in 2016–2025.
In univariable analysis, second alloHCT in 2016 or later was associated with improved OS (hazard ratio [HR], 0.50; 95% CI, 0.30–0.80; P=0.01) and PFS (HR, 0.50; 95% CI, 0.30–0.90; P=0.01), whereas CR3 or later and not being in CR were associated with inferior OS and PFS. Age, HCT-Comorbidity Index, donor type, conditioning intensity, GVHD prophylaxis, and graft source were not associated with OS or PFS. In multivariable analysis, transplant era independently predicted OS, while disease status independently predicted OS and PFS. Second alloHCT in 2016 or later remained associated with improved OS (HR, 0.54; 95% CI, 0.29–0.98; P=0.044) and showed a nonsignificant trend toward improved PFS (HR, 0.60; 95% CI, 0.33–1.10; P=0.098). Compared with CR2, CR3 or later and not being in CR were independently associated with inferior OS (HR, 2.18; P=0.049 and HR, 2.23; P=0.028, respectively) and PFS (HR, 2.31; P=0.029 and HR, 2.18; P=0.034, respectively).
Outcomes improved substantially in the contemporary era. Among patients transplanted in 2001–2015 versus 2016–2025, 4-year OS was 20% (95% CI, 9%–35%) versus 45% (95% CI, 27%–61%), with median OS of 7.1 versus 36.6 months; 4-year PFS was 20% (95% CI, 9%–34%) versus 46% (95% CI, 28%–61%), with median PFS of 4.4 versus 43.6 months. Four-year NRM and relapse were numerically lower in 2016–2025 than in 2001–2015 (23% vs 33% and 29% vs 44%, respectively). Overall, 4-year OS, PFS, NRM, and relapse were 33% (95% CI, 22%–44%), 33% (95% CI, 22%–44%), 27% (95% CI, 19%–40%), and 37% (95% CI, 27%–50%), respectively; median OS and PFS were 14.0 and 5.8 months. In the overall cohort, Grade 2–4 and grade 3–4 acute GVHD occurred in 28% and 5% by day 100, respectively, and 4-year chronic GVHD was 25%.
Conclusion
Second alloHCT provided meaningful long-term survival in selected adults with ALL relapsing after a first alloHCT. Outcomes improved markedly in the contemporary era, with 4-year OS and PFS increasing from 20% in 2001–2015 to approximately 45% in 2016–2025, accompanied by lower NRM and relapse. These improvements may reflect advances in salvage and bridging therapies, disease assessment, donor availability, GVHD prophylaxis, infection prevention, and supportive care. Disease status before second alloHCT remained the strongest prognostic factor, with patients transplanted in CR2 experiencing the most favorable OS and PFS. These findings support second alloHCT as a potentially curative option for appropriately selected patients and underscore the importance of achieving remission before transplantation.
DISCLOSURES
Mousa Thalji, MD: No relevant conflicts of interest to declare.